Accredited Investors’s Moderna MRNA Stock Holding History

Accredited Investors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,363	Closed	-$245K	–	196
2022 Q4	$245K	Buy	+1,363	New	+$223K	0.02%	157

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Accredited Investors's MRNA Position: Q1 2023 in Review

Accredited Investors sold out of Moderna (MRNA) in Q1 2023, closing a stake of 1,363 shares — an estimated $245K sold.

Accredited Investors first reported a position in MRNA in Q4 2022 and held it in 1 quarter. The position peaked at $245K in Q4 2022. 1,015 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

Accredited Investors reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
Accredited Investors sold 1,363 Moderna shares in Q1 2023, an estimated $245K.
Accredited Investors first reported a position in Moderna in Q4 2022 and held it in 1 quarter.
Accredited Investors's Moderna position peaked at $245K in Q4 2022.
1,015 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on Accredited Investors's 13F filing for Q1 2023, filed 24 Apr 2023.